ES2615120T3 - Adyuvantes peptídicos - Google Patents
Adyuvantes peptídicos Download PDFInfo
- Publication number
- ES2615120T3 ES2615120T3 ES15159788.7T ES15159788T ES2615120T3 ES 2615120 T3 ES2615120 T3 ES 2615120T3 ES 15159788 T ES15159788 T ES 15159788T ES 2615120 T3 ES2615120 T3 ES 2615120T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- peptide
- response
- weeks
- immunization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title description 9
- 239000002671 adjuvant Substances 0.000 title description 3
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 2
- DLQPMEMYCIGJIM-UHFFFAOYSA-N Adjuvant peptide Natural products CC(NC(=O)CCOC1C(O)C(CO)OC(O)C1NC(=O)C)C(=O)NC(CCC(=O)O)C(=O)N DLQPMEMYCIGJIM-UHFFFAOYSA-N 0.000 abstract 1
- BSOQXXWZTUDTEL-QAQREVAFSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-QAQREVAFSA-N 0.000 abstract 1
- 230000004044 response Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940124884 Engerix-B Drugs 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11853308P | 2008-11-28 | 2008-11-28 | |
| US118533P | 2008-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2615120T3 true ES2615120T3 (es) | 2017-06-05 |
Family
ID=42225170
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15159788.7T Active ES2615120T3 (es) | 2008-11-28 | 2009-11-30 | Adyuvantes peptídicos |
| ES09828499.5T Active ES2541443T3 (es) | 2008-11-28 | 2009-11-30 | Adyuvantes peptídicos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09828499.5T Active ES2541443T3 (es) | 2008-11-28 | 2009-11-30 | Adyuvantes peptídicos |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8404243B2 (enExample) |
| EP (2) | EP2370100B1 (enExample) |
| JP (2) | JP5656857B2 (enExample) |
| AU (2) | AU2009319667B2 (enExample) |
| CA (1) | CA2740566C (enExample) |
| ES (2) | ES2615120T3 (enExample) |
| NZ (1) | NZ593200A (enExample) |
| WO (1) | WO2010060208A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758548B2 (en) * | 2011-05-11 | 2017-09-12 | Technion Research & Development Foundation Limited | Anti-microbial peptides and uses of same |
| WO2013154744A1 (en) | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
| CA3100236A1 (en) * | 2020-11-20 | 2022-05-20 | Universite Laval | Severe acute respiratory syndrome coronavirus dna vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| GB9425582D0 (en) * | 1994-12-19 | 1995-02-15 | Iaf Biochem Int | Peptides having immunomodulatory activity |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US7371837B2 (en) * | 2004-07-21 | 2008-05-13 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
-
2009
- 2009-11-30 AU AU2009319667A patent/AU2009319667B2/en not_active Ceased
- 2009-11-30 EP EP09828499.5A patent/EP2370100B1/en not_active Not-in-force
- 2009-11-30 CA CA2740566A patent/CA2740566C/en not_active Expired - Fee Related
- 2009-11-30 EP EP15159788.7A patent/EP2987502B1/en not_active Not-in-force
- 2009-11-30 US US13/129,514 patent/US8404243B2/en not_active Expired - Fee Related
- 2009-11-30 ES ES15159788.7T patent/ES2615120T3/es active Active
- 2009-11-30 ES ES09828499.5T patent/ES2541443T3/es active Active
- 2009-11-30 NZ NZ593200A patent/NZ593200A/xx not_active IP Right Cessation
- 2009-11-30 WO PCT/CA2009/001707 patent/WO2010060208A1/en not_active Ceased
- 2009-11-30 JP JP2011537804A patent/JP5656857B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/833,523 patent/US9211325B2/en not_active Expired - Fee Related
-
2014
- 2014-11-21 JP JP2014237037A patent/JP5901084B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-11 AU AU2016201589A patent/AU2016201589B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2740566A1 (en) | 2010-06-03 |
| ES2541443T3 (es) | 2015-07-20 |
| AU2009319667A1 (en) | 2011-06-23 |
| AU2016201589B2 (en) | 2016-11-24 |
| US8404243B2 (en) | 2013-03-26 |
| EP2987502A1 (en) | 2016-02-24 |
| JP2015091811A (ja) | 2015-05-14 |
| NZ593200A (en) | 2012-10-26 |
| EP2370100A1 (en) | 2011-10-05 |
| WO2010060208A1 (en) | 2010-06-03 |
| CA2740566C (en) | 2017-11-28 |
| US9211325B2 (en) | 2015-12-15 |
| EP2370100A4 (en) | 2013-05-22 |
| JP5901084B2 (ja) | 2016-04-06 |
| AU2016201589A1 (en) | 2016-03-31 |
| EP2987502B1 (en) | 2016-11-09 |
| AU2009319667B2 (en) | 2016-03-03 |
| JP5656857B2 (ja) | 2015-01-21 |
| EP2370100B1 (en) | 2015-04-08 |
| JP2012509906A (ja) | 2012-04-26 |
| US20110305720A1 (en) | 2011-12-15 |
| US20130323285A1 (en) | 2013-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2488941T3 (es) | Vectores y constructos de liberación de antígenos de virus de la gripe | |
| JP4484904B2 (ja) | Ｄｎａ転写ユニットの接種による免疫化 | |
| Kamijuku et al. | Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses | |
| JP2022023102A (ja) | 新規多価ナノ粒子に基づくワクチン | |
| US9545439B2 (en) | Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase | |
| Romeli et al. | Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| RU2008102930A (ru) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки | |
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| CZ290826B6 (cs) | Vakcína | |
| ES2351489T3 (es) | Vacunas mejoradas. | |
| ES2615120T3 (es) | Adyuvantes peptídicos | |
| Dong et al. | Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice | |
| JP2013545448A5 (enExample) | ||
| BR112021001188A2 (pt) | composição que contém vacina contra a influenza | |
| Starodubova et al. | Rabies vaccines: Current status and prospects for development | |
| Dabaghian et al. | A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice | |
| ES2564183T3 (es) | Adyuvantes de vacuna | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| Jiang et al. | Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines | |
| Sato et al. | Induction of virus-specific cell-mediated cytotoxic responses of isogeneic ginbuna crucian carp, after oral immunization with inactivated virus | |
| Olszewska et al. | Nasal delivery of epitope based vaccines | |
| WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
| JP2012509906A5 (enExample) | ||
| ES2393546T3 (es) | Formulación de vacuna potenciada mediante la combinación de un ADN con un antígeno |